These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 16374156)

  • 21. Blood purification in the intensive care unit.
    Ponikvar R
    Nephrol Dial Transplant; 2003 Jul; 18 Suppl 5():v63-7. PubMed ID: 12817075
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended daily dialysis vs. continuous hemodialysis for ICU patients with acute renal failure: a two-year single center report.
    Kumar VA; Yeun JY; Depner TA; Don BR
    Int J Artif Organs; 2004 May; 27(5):371-9. PubMed ID: 15202814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Application of Pharmacokinetics: Basis for Rational Dose Selection in a Critically Ill Patient on Renal Replacement Therapy.
    Janković SM
    Eur J Drug Metab Pharmacokinet; 2019 Jun; 44(3):433-436. PubMed ID: 30426361
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended daily dialysis in acute kidney injury patients: metabolic and fluid control and risk factors for death.
    Ponce D; Abrão JM; Albino BB; Balbi AL
    PLoS One; 2013; 8(12):e81697. PubMed ID: 24349114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacokinetics of meropenem in critically ill patients with severe infections.
    Binder L; Schwörer H; Hoppe S; Streit F; Neumann S; Beckmann A; Wachter R; Oellerich M; Walson PD
    Ther Drug Monit; 2013 Feb; 35(1):63-70. PubMed ID: 23318279
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Inadequate antibiotic dosing in patients receiving sustained low efficiency dialysis.
    Keough LA; Krauss A; Hudson JQ
    Int J Clin Pharm; 2018 Oct; 40(5):1250-1256. PubMed ID: 30051232
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetic and Pharmacodynamic Characteristics of Vancomycin and Meropenem in Critically Ill Patients Receiving Sustained Low-efficiency Dialysis.
    Oliveira MS; Machado AS; Mendes ET; Chaves L; Perdigão Neto LV; Vieira da Silva C; Cavani Jorge Santos SR; Sanches C; Macedo E; Levin AS
    Clin Ther; 2020 Apr; 42(4):625-633. PubMed ID: 32199609
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of regional citrate anticoagulation for continuous sustained low efficiency dialysis (C-SLED) in critically ill patients.
    Finkel KW; Foringer JR
    Ren Fail; 2005; 27(5):541-5. PubMed ID: 16152991
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacokinetics of meropenem in critically ill patients receiving continuous venovenous haemofiltration: a randomised controlled trial of continuous infusion versus intermittent bolus administration.
    Jamal JA; Mat-Nor MB; Mohamad-Nor FS; Udy AA; Wallis SC; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2015 Jan; 45(1):41-5. PubMed ID: 25455853
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of meropenem in septic patients on sustained low-efficiency dialysis: a population pharmacokinetic study.
    Braune S; König C; Roberts JA; Nierhaus A; Steinmetz O; Baehr M; Kluge S; Langebrake C
    Crit Care; 2018 Jan; 22(1):25. PubMed ID: 29382394
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
    Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
    Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics of meropenem in patients with renal failure and patients receiving renal replacement therapy.
    Thalhammer F; Hörl WH
    Clin Pharmacokinet; 2000 Oct; 39(4):271-9. PubMed ID: 11069213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Amino acid losses during sustained low efficiency dialysis in critically ill patients with acute kidney injury.
    Umber A; Wolley MJ; Golper TA; Shaver MJ; Marshall MR
    Clin Nephrol; 2014 Feb; 81(2):93-9. PubMed ID: 24290407
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Extended daily veno-venous high-flux haemodialysis in patients with acute renal failure and multiple organ dysfunction syndrome using a single path batch dialysis system.
    Lonnemann G; Floege J; Kliem V; Brunkhorst R; Koch KM
    Nephrol Dial Transplant; 2000 Aug; 15(8):1189-93. PubMed ID: 10910443
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
    Mattioli F; Fucile C; Del Bono V; Marini V; Parisini A; Molin A; Zuccoli ML; Milano G; Danesi R; Marchese A; Polillo M; Viscoli C; Pelosi P; Martelli A; Di Paolo A
    Eur J Clin Pharmacol; 2016 Jul; 72(7):839-48. PubMed ID: 27048201
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Estimating the impact of renal replacement therapy choice on outcome in severe acute renal failure.
    Swartz RD; Bustami RT; Daley JM; Gillespie BW; Port FK
    Clin Nephrol; 2005 May; 63(5):335-45. PubMed ID: 15909592
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of meropenem plasma levels with pharmacodynamic requirements in critically ill patients receiving continuous veno-venous hemofiltration.
    Krueger WA; Neeser G; Schuster H; Schroeder TH; Hoffmann E; Heininger A; Dieterich HJ; Forst H; Unertl KE
    Chemotherapy; 2003 Dec; 49(6):280-6. PubMed ID: 14671427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of meropenem during intermittent and continuous intravenous application in patients treated by continuous renal replacement therapy.
    Langgartner J; Vasold A; Glück T; Reng M; Kees F
    Intensive Care Med; 2008 Jun; 34(6):1091-6. PubMed ID: 18297267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single- and multiple-dose pharmacokinetics and total removal of colistin in critically ill patients with acute kidney injury undergoing prolonged intermittent renal replacement therapy.
    Schmidt JJ; Strunk AK; David S; Bode-Böger SM; Martens-Lobenhoffer J; Knitsch W; Scherneck S; Welte T; Kielstein JT
    J Antimicrob Chemother; 2019 Apr; 74(4):997-1002. PubMed ID: 30624668
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Population Pharmacokinetic Analysis of Meropenem in Critically Ill Patients With Acute Kidney Injury Treated With Continuous Hemodiafiltration.
    Niibe Y; Suzuki T; Yamazaki S; Suzuki T; Takahashi N; Hattori N; Nakada TA; Oda S; Ishii I
    Ther Drug Monit; 2020 Aug; 42(4):588-594. PubMed ID: 32049890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.